Bronchogenic carcinoma

Summary

Bronchogenic carcinoma (MONDO:0002806) is a cancer and 8 clinical trials. Top therapeutic interventions include taletrectinib. A subtype of bronchus cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	bronchogenic carcinoma
Mondo ID	MONDO:0002806
EFO	EFO:1001942
MeSH	D002283
DOID	DOID:3904
NCIT	C35875
SNOMED CT	254622008
UMLS	C0007121
MedGen	2872
Anatomy (UBERON)	UBERON:0002185
Is cancer (heuristic)	yes

Also known as: bronchial carcinoma · bronchiogenic carcinoma · bronchogenic carcinoma · bronchogenic lung cancer · bronchogenic lung carcinoma · bronchus carcinoma · carcinoma of bronchus · carcinoma, bronchial, malignant

Data availability: 3 cell lines.

Disease family

This is a subtype of bronchus cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › respiratory system cancer › bronchus cancer › bronchogenic carcinoma

Related subtypes (1): main bronchus cancer

Subtypes (2): bronchus carcinoma in situ, bronchus mucoepidermoid carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Fluticasone Propionate.

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	4
PHASE2	2
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00652769	PHASE3	COMPLETED	A New Pathway With BronchOscopic or Oesophageal Ultrasound for Lung Cancer Diagnosis and STaging (BOOST)
NCT00196885	PHASE2	COMPLETED	Effect of an Antioxidant on Cancer-Cachectic Patients Undergoing Exercise Training
NCT00407264	PHASE2	COMPLETED	Randomized Trial of Fluticasone in Bronchial Premalignancy
NCT00001515	PHASE1	COMPLETED	Diagnostic Effectiveness of Virtual Bronchoscopy
NCT06971848	Not specified	NOT_YET_RECRUITING	Evaluation of Skin Tests in Biotherapy Allergies
NCT02270853	Not specified	UNKNOWN	SAS in Patients With Bronchial Carcinoma
NCT04517019	Not specified	UNKNOWN	Randomised Trial Evaluating the Benefit of a Fitness Tracker Based Workout During Radiotherapy
NCT06841874	Not specified	NO_LONGER_AVAILABLE	Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
TALETRECTINIB	2	1
CHEMBL5435500	0	1